Literature DB >> 16505116

Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.

Carolyn Cao1, Eric T Shinohara, Ty K Subhawong, Ling Geng, Kwang Woon Kim, Jeffrey M Albert, Dennis E Hallahan, Bo Lu.   

Abstract

p53 plays a critical role in cell cycle arrest and induction of apoptosis. Certain malignancies carry wild-type p53, which is frequently down-regulated by murine double minute 2 (MDM2) overexpression. Availability of a small-molecule inhibitor against MDM2, nutlin, has made it feasible to evaluate the anti-MDM2-based therapeutic strategies. The rationale for the current study is that functional p53 has been linked with improved responses to radiation treatment. Hence, this study evaluates the use of nutlin, a small-molecule inhibitor that blocks the interaction of p53 and MDM2, in sensitizing cancer cells to radiation. Expression of MDM2, p53, and p21 in both p53 wild-type and p53-defective lung cancer cell lines was examined. Clonogenic and 7-amino-actinomycin D studies were used to determine possible mechanisms of cell death. The combined effect of MDM2 inhibition and radiation on cell cycle was also studied. We found that radiosensitization by nutlin occurs in lung cancer cells with wild-type p53. There were increased apoptosis and cell cycle arrest following administration of nutlin and radiation. Furthermore, the combination of nutlin and radiation decreased the ability of endothelial cells to form vasculature, as shown by Matrigel assays. Our data suggest that nutlin is an effective radiosensitizer of p53 wild-type cells. The radiosensitizing effect seems to be at least partially due to induction of apoptosis and cell cycle arrest. In addition, nutlin may be an effective radiosensitizer of tumor vasculature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505116     DOI: 10.1158/1535-7163.MCT-05-0356

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  30 in total

1.  A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Authors:  Hongbo Wang; Xujun Ma; Shumei Ren; John K Buolamwini; Chunhong Yan
Journal:  Mol Cancer Ther       Date:  2010-11-12       Impact factor: 6.261

2.  Mycoplasma hyorhinis reduces sensitivity of human lung carcinoma cells to Nutlin-3 and promotes their malignant phenotype.

Authors:  Uljana A Boyarskikh; Alexandra S Shadrina; Mariya A Smetanina; Yakov A Tsepilov; Igor P Oscorbin; Vadim V Kozlov; Alexander E Kel; Maxim L Filipenko
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-08       Impact factor: 4.553

3.  A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.

Authors:  Hongbo Wang; Chunhong Yan
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

Review 4.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

Review 5.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

6.  Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels.

Authors:  Daniela Schilling; Michael Düwel; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2012-08-30       Impact factor: 3.667

7.  2-Deoxy-D-glucose and ferulic acid modulates radiation response signaling in non-small cell lung cancer cells.

Authors:  Venkata Reddy Bandugula; Rajendra Prasad N
Journal:  Tumour Biol       Date:  2012-10-12

Review 8.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

9.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Authors:  Andrew M Roberts; Ian R Watson; Andrew J Evans; David A Foster; Meredith S Irwin; Michael Ohh
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 10.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.